The treatment of metastatic renal cell carcinoma is challenging as it has proven to be relatively resistant to conventional oncological treatments. An improved understanding of the molecular biology of renal cell carcinoma has led to the development of a number of targeted therapies in metastatic renal cell carcinoma. This includes vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors and most recently immune checkpoint inhibitors. This article will review the mechanisms of development and progression of renal cell carcinoma as well as the mechanisms of current approved treatments in metastatic disease.
Level of evidence: Not applicable for this multicentre audit.
FerlayJColombetMSoerjomataramI, et al. GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
2.
EbleJNSauterGEpsteinJI, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, 2004.
3.
MochHCubillaALHymphreyPA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile and testicular tumours. Eur Urol2016; 70(1): 93–105.
4.
EscudierBPortaCSchmidingerM, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2016; 27(S5): v58–68.
5.
NooneAMHowladerNKrapchoM, et al. SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/ based on November2017 SEER data submission, posted to the SEER website, April 2018.
6.
JanzenNKKimHLFiglinRA, et al. Surveillance after radical or partial nephrectomy for localised renal cell carcinoma and management of recurrent disease. Urol Clin North Am2003; 30(4): 843–852.
7.
GuptaKMillerJDLiJZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev2008; 34(3): 193–205.
8.
BukowskiRM.Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin 2. Cancer1997; 80(7): 1198–1220.
9.
HartmannJTBokemeyerC.Chemotherapy for renal cell carcinoma. Anticancer Res1999; 19(2C): 1541–1543.
10.
De MeerleerGKhooVEscudierB, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol (2014) 15(4): e170–7.
11.
RosenbergSALotzeMTMuulLM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer. N Engl J Med1985; 313(23): 1485–1492.
12.
RosenbergSALotzeMTMuulLM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and Interleukin-2 or high-dose Interleukin-2 alone. N Engl J Med1987; 316(15): 889–897.
13.
AtzpodienJKörferAFranksCR, et al. Home therapy with recombinant Interleukin-2 and Interferon-alpha 2b in advanced human malignancies. Lancet1990; 335(8704): 1509–1512.
14.
RitchieAGriffithsGParmarM, et al. Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet1999; 353(9146): 14–17.
15.
DeckerWKda SilvaRFSanabriaMH, et al. Cancer immunotherapy: Historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol2017; 8:829.
16.
FyfeGFisherRIRosenbergSA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant Interleukin-2 therapy. J Clin Oncol1995; 13(3): 688–696.
17.
GillDMAgarwalNVaishampayanU.Evolving treatment paradigm in metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book2017; 37: 319–329.
18.
KaneRCFarrellATSaberH, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res2006; 12(24): 7271–7278.
19.
MotzerRJRiniBIMcDermottDF, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized Phase II trial. J Clin Oncology2015; 33(13): 1430–1437.
20.
MotzerRJEscudierBMcDermottDF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015; 373(19): 1803–1813.
21.
LonserRRGlennGMWaltherM, et al. von Hippel-Lindau disease. Lancet2003; 361(9374): 2059–2067.
22.
GnarraJRToryKWengY, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet1994; 7(1): 85–90.
23.
RazafinjatovoCBihrSMischoA, et al. Characterization of VHL missense mutations in sporadic clear cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer2016; 16: 638.
24.
SeizingerBRRouleauGAOzeliusLJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature1988; 332(6161): 268–269.
25.
HosoeSBrauchHLatifF, et al. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics1990; 8(4): 634–640.
26.
IliopoulosOLevyAPJuangC, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA1996; 93(20): 10595–10599.
27.
PauseALeeSWorrellRA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA1997; 94(6): 2156–2161.
28.
KamuraTKoeppDMConradMN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science1999; 284(5414): 657–661.
29.
StebbinsCEKaelinWCPavletichNP.Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science1999; 284(5413): 455–461.
30.
BárdosJIAshcroftM.Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays2004; 26(3): 262–269.
31.
ShweikiDItinASofferD, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature1992; 359(6398): 843–845.
32.
ForsytheJAJiangBIyerNV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol1996; 16(9): 4604–4613.
33.
PengXHKamaPCaoZ, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathway increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem2006; 281(36): 25903–25914.
34.
KlatteTSeligsonDBRiggsSB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res2007; 13(24): 7388–7393.
35.
SasakiTHirokiKYamashitaY.The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int2013; 546318.
36.
LeeJWBaeSHJeongJW, et al. Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Exp Mol Med2004; 36(1): 1–12.
37.
RavalRRLauKWTranMG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol2005; 25(13): 5675–5686.
38.
SchöffskiPDumezHClementP, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: A review. Ann Oncol2006; 17(8): 1185–1196.
39.
PaulMKMukhopadhyayAK.Tyrosine kinase – Role and significance in Cancer. Int J Med Sci2004; 1(2): 101–115.
40.
SangNStiehlDPBohenskyJ, et al. MAPK signalling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem2003; 278(16): 14013–14019.
LandSCTeeAR.Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signalling motif. J Biol Chem2007; 282(28) 20534–20543.
43.
LaplanteMSabatiniDM.mTOR signalling in growth control and disease. Cell2012; 149(2): 274–293.
44.
Shin LeeJSeok KimHBok KimY, et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behaviour and growth. J Surg Oncol2003; 84(3): 166–172.
45.
SathianathenNJKrishnaSAndersonJK, et al. The current status of immune-based therapies for metastatic renal-cell carcinoma. Immunotargets Ther2017; 6:83–93.
46.
Ménétrier-CauxCBainCFavrotMC, et al. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer1999; 79(1): 119–130.
47.
DiegmannJJunkerKLoncareviczIF, et al. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia2006; 8(11): 933–938.
48.
VinayDSRyanEPPawelecG, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol2015; 35: S185–98.
49.
PardollDM.The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012; 12(4): 252–264.
50.
GoldbergMVDrakeCG.LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol2011; 344: 269–278.
51.
SittigSPKøllgaardTGrønbækK, et al. Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunol2013; 2(9): e26014.
52.
BuchbinderEIDesaiA.CTLA-4 and PD-1 Pathways. Am J Clin Oncol2016; 39(1): 98–106.
53.
EscudierBBellmuntJNégrierS, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol2010; 28(13): 2144–2150.
54.
RiniBIHalabiSRosenbergJE, et al. Bevacizumab plus interferon alga compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol2008; 26(33): 5422–5428.
55.
RiniBIHalabiSRosenbergJE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol2010; 28(13): 2137–2143.
56.
RatainMJEisenTStadlerWM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol2006; 24(16): 2505–2512.
57.
EscudierBEisenTStadlerWM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med2007; 356(2):125–134.
58.
MotzerRJMichaelsonMDRosenbergJ, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol2007; 178(5): 1883–1887.
59.
MotzerRJHutsonTETomczakP, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009; 27(22): 3584–3590.
60.
SternbergCNDavisIDMardiakJ, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trial. J Clin Oncol2010; 28(6): 1061–1068.
61.
SternbergCNHawkinsREWagstaffJ, et al. A randomised, double-blind Phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer2013; 49(6): 1287–1296.
62.
MotzerRJNosovDEisenT, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a Phase III trial. J Clin Oncol2013; 31(30): 3791–3799.
63.
ChoueiriTKEscudierBPowlesT, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma. N Eng J Med2015; 373(19): 1814–1823.
64.
ChoueiriTKEscudierBPowlesT, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, Phase 3 trial. Lancet Oncol2016; 17(7): 917–927.
65.
ChoueiriTKHesselCHalabiS, et al. Cabozantinib versus sunitinib as initial targeted therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer2018; 94: 115–125.
66.
MotzerRJHutsonTEGlenH, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, Phase 2, open-label, multicentre trial. Lancet Oncol2015; 16(15): 1473–1482.
67.
MotzerRJEscudierBTomczakP, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised Phase 3 trial. Lancet Oncol2013; 14(6): 552–562.
68.
HudesGCarducciMTomczakP, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007; 356(22): 2271–2281.
69.
MotzerRJEscudierBOudardS, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer2010; 116(18): 4256–4265.
70.
MotzerRJTannirNMMcDermottDF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med2018; 378(14): 1277–1290.
71.
CarmelietP.VEGF as a key mediator of angiogenesis in cancer. Oncology2005; 69(S3): 4–10.
72.
NICE. Bevacizumab (first-line), sorafenib (first- and second- line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. [TA178]. Available at: https://www.nice.org.uk/guidance/ta178/chapter/4-Evidence-and-interpretation (2009, accessed 14 January 2019).
ClinicalTrials.gov. Study to evaluate safety, pharmacokinetics and therapeutic activity of RO6874281 as a combination therapy in participants with unresectable advanced and/or metastatic renal cell carcinoma (RCC). ClinicalTrials.gov Identifier: NCT03063762. Available from: https://clinicaltrials.gov/ct2/show/NCT03063762?term=Bevacizumab&recrs=abdf&cond=Renal&rank=8 (accessed 14 January 2019).
75.
MotzerRJPowlesTAtkinsMB, et al. IMmotion151: A randomized Phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol2018; 36(6): 578.
76.
GotinkKJVerheulHM.Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action?Angiogenesis2010; 13(1): 1–14.
77.
DyGKAjeiAA.Understanding, recognizing and managing toxicities of targeted anticancer therapies. CA Cancer J Clin2013; 63(4): 249–279.
78.
NICE. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. [TA333] Available at: https://www.nice.org.uk/guidance/ta333/resources (2015, accessed 15 January 2019).
NeshatMSMellinghoffIKTranC, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Aca Sci USA2001; 98(18): 10314–10319.
83.
AtkinsMBHidalgoMStadlerWM, et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol2004; 22(5): 909–918.
84.
NICE. Everolimus for advanced renal cell carcinoma after previous treatment. [TA432] Available at: https://www.nice.org.uk/guidance/ta432 (2017, accessed 15 January 2019).
85.
MotzerRJEscudierBOudardS, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet2008; 372(9637): 449–456.
86.
LeeSMargolinK.Cytokines in cancer immunotherapy. Cancers (Basel)2011; 3(4): 3856–3893.
87.
KoneruRHotteSJ.Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr Oncol2009; 16(S1): S40–4.
88.
YangJCHughesMKammulaU, et al. Ipilimumab (Anti-CTLA4 Antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother2007; 30(8): 825–830.
Di LorenzoGPortaCBellmuntJ, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol2011; 59(4): 526–540.
92.
DuranILambeaJMarotoP, et al. Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action. Target Oncol2017; 12(1): 19–35.
MaruSIshigakiYShinoharaN, et al. Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma. J Urol2013; 189(5): 1921–1929.
95.
ChenWHillHChristieA, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature2016; 539(7627): 112–117.
96.
CourtneyKDInfanteJRLamET, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol2018; 36(9): 867–874.
97.
HigginsJPShinghalRGillH, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol2003; 162(3): 925–932.
